Shares of Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, one has assigned a buy recommendation and two have assigned a strong buy recommendation to the company.
Several brokerages have commented on RHHBY. HSBC downgraded Roche from a “buy” rating to a “hold” rating in a research note on Monday, April 28th. Hsbc Global Res cut Roche from a “strong-buy” rating to a “hold” rating in a report on Monday, April 28th.
Get Our Latest Stock Report on RHHBY
Institutional Inflows and Outflows
Roche Stock Down 1.0%
Shares of RHHBY opened at $38.23 on Friday. Roche has a 1 year low of $34.10 and a 1 year high of $44.31. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.20 and a current ratio of 1.48. The stock’s fifty day moving average price is $40.29 and its two-hundred day moving average price is $40.28.
Roche Company Profile
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
See Also
- Five stocks we like better than Roche
- The Basics of Support and Resistance
- 3 Dividend Stocks Raising Payouts—and Backing It Up With Results
- What is the NASDAQ Stock Exchange?
- 3 Stocks With Monopoly Power—and Minimal Competition
- 3 Fintech Stocks With Good 2021 Prospects
- Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.